Propranolol treatment for deep infantile hemangiomas on the parotid area: a report of 23 cases

Abstract

Abstract: PURPOSE : To evaluate the efficacy and safety of propranolol for the treatment of deep infantile hemangiomas(IH) on the parotid area. METHODS : Oral propranolol at a dose of 1.0-1.5 mg/kg three times per day was administered to 23 deep parotid IHs.The duration of treatment ranged from 6 to 10 months. The changes of the tumor colour and texture were monitored and recorded at a regular interval. At the same time, size was documented by ultrasound echo color doppler. The adverse effects after medication were observed and managed accordingly. To assess the efficacy, a 4 scales system was adopted. RESULTS : The average propranolol treatment duration for the 23 patients was 7.8 months, the overall response was slight in 0 patient，moderate in 1 patients, good in 4 patients，and excellent in 18 patients. No serious adverse events were encountered.A second course of propranolol readily controlled the rebound growth of deep IH in 3 patients(13%). CONCLUSIONS : Propranolol yielded excellent results with very good clinical tolerance and also seems to be effective for IH rebound growth. The optimal duration of the treatment remains to be defined by long-term observation.

Key words: Deep infantile hemangiomas, Parotid gland, Propranolol

CLC Number:

R739.8

SI Ya-meng, MENG Jian, ZHANG Xing, ZHANG Ai-xia, ZHENG Hao, WEI Jing-jian.. Propranolol treatment for deep infantile hemangiomas on the parotid area: a report of 23 cases[J]. China Journal of Oral and Maxillofacial Surgery, 2015, 13(6): 530-533.

References

[1] Phung TL, Hochman M, Mihm MC, et al. Current knowledge of the pathogenesis of infantile hemangiomas [J]. Arch Facial Plast Surg, 2005, 7(5): 319-321.
[2] Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J, et al. Propranolol for treatment of ulcerated infantile hemangiomas [J]. J Am Acad Dermatol, 2011, 64(5): 827-832.
[3] Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients [J]. Plast Reconstr Surg, 1997, 99(5): 1301-1308.
[4] Waner M, Suen JY. Management of congenital vascular lesions of the head and neck [J]. Oncology(Williston Park), 1995, 9(10): 989-994, 997.
[5] 麦华明, 郑家伟, 张凌, 等. 普萘洛尔对血管瘤中HemSC凋亡和VEGF、bFGF表达的影响及临床意义 [J]. 中国口腔颌面外科杂志, 2013, 11(4): 287-296.
[6] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [J]. N Engl J Med, 2008, 358(24): 2649-2651.
[7] Marqueling AL, Oza V, Frieden IJ, et al. Propranolol and infantile hemangiomas four years later: a systematic review [J]. Pediatr Dermatol, 2013, 30(2): 182-191.
[8] Weiss I, O TM, Lipari BA, et al. Current treatment of parotid hemangiomas [J]. Laryngoscope, 2011, 121(8): 1642-1650.
[9] Georgountzou A, Karavitakis E, Klimentopoulou A, et al. Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience [J]. Acta Paediatr, 2012, 101(10): 469-474.
[10] Neri I, Balestri R, Patrizi A. Hemangiomas: new insight and medical treatment [J]. Dermatol Ther, 2012, 25(4): 322-334.
[11] Giachetti A, Garcia-Monaco R, Sojo M, et al. Long-term treatment with oral propranolol reduces relapses of infantile hemangiomas [J]. Pediatr Dermatol, 2014, 31(1): 14-20.
[12] Lynch M, Lenane P, O'Donnell BF. Propranolol for the treatment of infantile haemangiomas:
our experience with 44 patients [J]. Clin Exp Dermatol, 2014, 39(2): 142-145.
[13] Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms [J]. Br J Dermatol, 2010, 163(2): 269-274.

[1]	ZHENG Jia-wei, WANG Xu-kai, QIN Zhong-ping, FAN Xin-dong, LI Kai, YANG Yao-wu, HUO Ran, LIU Shao-hua, ZHAO Ji-hong, WANG Xiao-yong, ZHOU De-kai, LIU Xue-jian. Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas(version 2022) [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(4): 313-319.
[2]	FANG Yi-kang, HAN Lin-zi, SHENG Shan-gui, YAN Ting-ting, WANG He-jing, YUAN Rong-tao. Parotid gland atrophy caused by residual butter after orbital trauma: a case report, literature review [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(3): 310-312.
[3]	QU Jun-chen, JIA Chuan-hai, DING Qing-guo, CAO Rui, QIU Jia-ming. Evaluation of MRI image texture analysis in differential diagnosis of benign, malignant parotid gland tumors [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(2): 173-176.
[4]	YUAN Xu-guang, ZHU Jun-fei, LI Tian-zhu, GUANG Meng-kai, ZHANG Ye. Unilateral parotid gland involvement with 2 different pathological tumors: a case report [J]. China Journal of Oral and Maxillofacial Surgery, 2021, 19(1): 94-96.
[5]	WANG Qi-zhang, ZHENG Jia-wei. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines (translation version) [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(6): 548-552.
[6]	XU Fei-hu, LIU Li-min, XU Wan-lin, LIU Sheng-wen, YANG Wen-jun. A case of Castleman's disease in the parotid gland of children and review of literature [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(6): 567-570.
[7]	LIU Sheng-wen, YANG Wen-jun, WANG Li-zhen, YUAN Fang. Clinicopathologic studies of lymphadenoma of the parotid gland in 15 cases [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(5): 451-456.
[8]	GU Da, HUO Ran, XU Guang-qi, BI Jian-hai, LI Shang-bin. Progress in topical of application β-blockers in the treatment of infantile hemangioma [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(4): 375-380.
[9]	LI Hong, ZHOU Yu-chuan, GONG Zhong-cheng, SUN Yang, LING Bin. Oral propranolol combined with topical betaxolol for 8 children with high-risk infantile hemangiomas involving periocular region [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(3): 264-268.
[10]	SONG Hui-xin, LIN Chun-nan, WANG Tian-you, FU Zhao-chen. Advances in research on the mechanism of propranolol in the treatment of infantile hemangiomas [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(2): 182-185.
[11]	YUAN Zhen-ying, LI Ming, GUAN Cui-qiang, YAN Xing-quan, NAN Xin-rong. Parotid T cell lymphoma: a case report and literature review [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(2): 186-189.
[12]	FENG Lin-fei, WU Jiang-en, XUE Hao-wei, HOU Jun. Application of electromyography to evaluating facial nerve function [J]. China Journal of Oral and Maxillofacial Surgery, 2019, 17(6): 522-525.
[13]	ZHENG Ya-feng, ZHOU Xia, SHANG Fei-fei, MA Lian. Phenotype study of parotid gland in 140 patients with first and second branchial arch syndrome [J]. China Journal of Oral and Maxillofacial Surgery, 2019, 17(5): 444-447.
[14]	LIU Shi-qi, YANG Liang-hui, CHEN Guo-sheng, WANG hui, FANG fang, LIAO Xian-xiang, MAI Hua-ming. The expression of beta adrenergic receptor in CAL-27 cell line of tongue carcinoma and the effects of beta blockers on proliferation, migration and invasion [J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(5): 391-396.
[15]	ZHENG Kai, NI Xiao-jie, SHI Wu-chao, HU Si-tong, SUN Dian, CHEN Yi-ping, DING Yu-yuan, SHENG Mei-ying, XIAO Can. Cystic lymphoepithelial hyperplasia of parotid gland in a HIV-positive patient: case report and review of literature [J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(1): 93-96.